119514-24-8

Basic information

• Product Name: 4-(thiazol-2-yl)phenol
• Synonyms: 4-(thiazol-2-yl)phenol
• CAS NO: 119514-24-8
• Molecular Formula: C₁₀H₆F₃NS
• Molecular Weight: 229.2215
• Mol File: 119514-24-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 277.5 °C at 760 mmHg
• Flash Point: 121.6 °C
• Appearance: /
• Density: 1.341 g/cm³
• Vapor Pressure: 0.00761mmHg at 25°C
• Refractive Index: 1.524
• CAS DataBase Reference: 4-(thiazol-2-yl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(thiazol-2-yl)phenol(119514-24-8)
• EPA Substance Registry System: 4-(thiazol-2-yl)phenol(119514-24-8)

Safety Data

• Hazardous Substances Data: 119514-24-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H6F3NS/c11-10(12,13)8-3-1-7(2-4-8)9-14-5-6-15-9/h1-6H

Upstream product

• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 72505-21-6 4-trifluoromethylbenzthioamide 
• 288-47-1 1,3-thiazole 
• 455-13-0 4-Iodobenzotrifluoride 
• 3034-53-5 2-bromo-1,3-thiazole 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 455-24-3 4-trifluoromethylbenzoic acid 
• 15873-56-0 monochloroacetaldehyde hydrate 
• 174006-70-3 2-(4-(trifluoromethyl)phenyl)thiazole-4-carbaldehyde 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 857284-25-4 {2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-4-yl}methanol 

Downstream Products

• 119514-25-9 2-(4-trifluoromethylphenyl)-5-iodothiazole 
• 72505-21-6 4-trifluoromethylbenzthioamide 
• 1000029-30-0 5-(4-nitrophenyl)-2-(4-trifluoromethylphenyl)thiazole 
• 1000029-28-6 5-(4-chlorophenyl)-2-(4-trifluoromethylphenyl)thiazole 
• 1000029-29-7 5-(4-methylphenyl)-2-(4-trifluoromethylphenyl)thiazole 
• 1000029-31-1 5-(4-methoxyphenyl)-2-(4-trifluoromethylphenyl)thiazole 
• 1429329-83-8 1-(pyridin-4-yl)-1-(2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethanol 
• 1370731-82-0 5-phenyl-2-[4-(trifluoromethyl)phenyl]thiazole 

Relevant articles and documents

Bimetallic Cooperative Catalysis for Decarbonylative Heteroarylation of Carboxylic Acids via C-O/C-H Coupling

Cooperative bimetallic catalysis is a fundamental approach in modern synthetic chemistry. We report bimetallic cooperative catalysis for the direct decarbonylative heteroarylation of ubiquitous carboxylic acids via acyl C-O/C-H coupling. This novel catalytic system exploits the cooperative action of a copper catalyst and a palladium catalyst in decarbonylation, which enables highly chemoselective synthesis of important heterobiaryl motifs through the coupling of carboxylic acids with heteroarenes in the absence of prefunctionalization or directing groups. This cooperative decarbonylative method uses common carboxylic acids and shows a remarkably broad substrate scope (>70 examples), including late-stage modification of pharmaceuticals and streamlined synthesis of bioactive agents. Extensive mechanistic and computational studies were conducted to gain insight into the mechanism of the reaction. The key step involves intersection of the two catalytic cycles via transmetallation of the copper–aryl species with the palladium(II) intermediate generated by oxidative addition/decarbonylation.

BENZOBIS(THIADIAZOLE)DERIVATIVE, INK COMPRISING THE SAME, AND ORGANIC ELECTRONICS DEVICE USING THE SAME

PROBLEM TO BE SOLVED: To provide benzobis(thiadiazole) derivative excellent in electron mobility (electric field-effect mobility), excellent in stability in atmosphere and having a novel skeleton, and to provide an organic electronics device. SOLUTION: There is provided the benzobis(thiadiazole) derivative represented by formula (1), where Ar1 is a five-membered ring heteroarylene group comprising at least one atom selected from N, S, O and Se, Ar2 is a phenyl group, six-membered ring heteroaryl group comprising one or more N or five-membered ring heteroaryl group comprising at least one atom selected from N, S, O and Se, excluding a case in which Ar1 is a thiophene group and Ar2 is a phenyl group. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

PYRIDINE DERIVATIVES

The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP 17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.